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Chronic obstructive pulmonary disease (COPD) is characterized by an airways inflammation and by an enhanced generation of reactive
oxygen species. The aim of our study was to assess the inflammation and the oxidative stress in airways of COPD patients with acute
exacerbation of disease and in stability. Furthermore, we investigated the anti-inflammatory and antioxidant effects of 6 months treatment
with carbocysteine lysine salt monohydrate (SCMC-Lys) in COPD. We studied 30 mild acute COPD, 10 mild stable COPD and 15 healthy
subjects. 8-isoprostane and Interleukine-6 were measured in their breath condensate through immunoassay. Significantly higher
concentrations of exhaled 8-isoprostane and Interleukine-6 were found in acute COPD patients compared to stable COPD and healthy
controls (21.8F5.1 vs. 13.2F2.0 vs. 4.7F1.8 pg/ml and 7.4F0.9 vs. 5.8F0.2 vs. 2.7F0.6 pg/ml, pb0.0001). COPD patients treated with
SCMC-Lys showed a marked reduction of exhaled 8-isoprostane and Interleukine-6 (8.9F1.5 and 4.6F0.8 pg/ml, pb0.0001). These findings
suggest that there is an increase of 8-isoprostane and Interleukine-6 concentrations in the breath condensate of COPD patients compared to
healthy controls especially during acute exacerbations of the disease. Moreover, we showed an anti-inflammatory and antioxidant effect of
short-term administration of SCMC-Lys in COPD, suggesting the importance of a further placebo-controlled study that should evaluate the
effects of this drug.
D 2004 Elsevier B.V. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is
predicted to become the third most common cause of death
and the fifth most common cause of disability in the word
by 2020 (Lopez and Murray, 1998).0014-2999/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2004.10.007
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0805301321; fax: +39 0805045362.
E-mail address: ge.carpagnano@unifg.it (G.E. Carpagnano).The airways inflammation and the increased production
of reactive oxygen species in the lung play a key role in the
pathogenesis of this widespread respiratory disease (Barnes,
2003; Paredi et al., 2002; MacNee, 2001). Although
bronchoepitelial cells contain high levels of antioxidant to
compete with such oxidants, in COPD, they are inadequate.
Therefore, it is realized an oxidant-mediated epithelial
injury that finish to damage the epithelial surface of airways
by peroxidizing lipids, disrupting proteins and deoxyribo-
nucleic acid (DNA; Brandolini et al., 2003; Kasielski and
Nowak, 2001; Pinamonti et al., 1996).logy 505 (2004) 169–175
Table 1
Subject characteristics
Mild acute
COPD
Mild stable
COPD
Healthy
subjects
Number 30 10 15
Age (yr) 51F6 50F4 48F7
Sex (M/F) 19/11 5/5 8/7
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and oxidative stress markers such as Interleukin-6, Leuko-
triene B4 (LTB4), 8-isoprostane, hydrogen peroxide (H2O2)
and ethane in breath condensate of COPD subjects
(Biernacki et al., 2003; Carpagnano et al., 2003a,b;
Dekhuijzen et al., 1996; Montuschi et al., 2000; Paredi et
al., 2000). This new method to collect sample from airways,
the breath condensate, has recently arouses interest in
research and clinic for its simplicity, practicability, non-
invasiveness and especially for the great acceptance by
patients (Kharitonov and Barnes, 2001a,b).
The inflammation and the oxidative stress further
raise during periods of acute exacerbations of COPD
that are known to represent the most common cause of
hospitalization and of health care costs (Biernacki et al.,
2003; Fletcher and Peto, 1977; Kanner et al., 2001).
Also, the mucus hypersecretion, hallmark of COPD,
seems to get worse during the exacerbations (Schreiber
et al., 2002).
Notwithstanding the key role of mucous in aggravate
airflow obstruction, the value of mucolytic therapy is
unrecognized at a point that the European Respiratory
Society and the American Thoracic Society COPD guide-
lines discouraged the use of mucolytic in treatment of
patients with stable and/or acute COPD (American
Thoracic Society Standards, 1995 guidelines; British
Thoracic Society guidelines, 1997; Schreiber et al.,
2002). Of late, the point of view of researchers and
clinicians at this regard seems starting to change inasmuch
as some thiol-containing mucolytic drugs (sodium 2-
mercaptoethane sulphonate and N-acetylcysteine) showed
associated with their therapeutical effect, anti-inflammatory
and antioxidant capabilities (Gressier et al., 1994; Kasielski
and Nowak, 2001).
Only recently also, the thioether group contained in
carbocysteine lysine salt monohydrate (SCMC-Lys) has
been found to have some capacities to reduce airways
inflammation (Barnes, 2003; Pfeifer et al., 1997).
The purpose of the present work was to assess the
inflammation and the oxidative stress in airways of COPD
patients during an acute exacerbation of diseases and in
stability. Furthermore, we studied the anti-inflammatory
and antioxidant effects of SCMC-Lys in COPD patients
measuring an inflammatory (Interleukine-6) and an oxida-
tive stress marker (8-isoprostane) in their breath conden-
sate before and after 6 months of SCMC-Lys
administration.FEV1
(%predicted)
74.4F2.6 78F3.1 101F18%
FVC
(%predicted)
84.2F1.8 87F2.8 119F9%
PaO2
(mm Hg)
76.7F3.5 83F2.3 96.1F2.7
PaCO2
(mm Hg)
39.8F2.1 37F1.2 36.3F2.5
Definition of abbreviations: FEV1—forced expiratory volume in one
second; FVC—forced vital capacity. All data are expressed as meansFS.D.2. Methods
2.1. Study population
We studied 40 ex-smoker patients with mild COPD
(cigarette consumption 32F5 pack/years) and 15 non-
smoker healthy subjects with no history of lung disease(Table 1). All subjects were recruited from the Respiratory
Disease Institute, University of Bari, and written informed
consent was obtained from all subjects. The study was
approved by the Institutional Ethics Committee. The
diagnosis of COPD was based on GOLD Guidelines
(Pauwels et al., 2001). All COPD patients were ex-smokers,
had stopped smoking for at least 1 year, had no history of
allergic diseases, peptic ulcer or intestinal malabsorption,
were not suffering from chronic congestive heart failure and
did not use domiciliary oxygen (PaO2N60%). Healthy
subjects had never smoked, had no respiratory symptoms
and had no respiratory tract infection for z3 months prior to
the study. Exclusion criteria were a known allergy to
carbocysteine lysine salt monohydrate (SCMC-Lys).
Thirty COPD patients were enrolled in this study at
the hospital admission for treatment of acute exacerba-
tions. Ten patients with stable COPD, used as a control
group, were enrolled during semester check visit. An
acute exacerbation was defined as worsening of the
previous stable clinical status with presence of at least
one of the following: increased sputum purulence and/or
volume, increased dyspnea, wheeze or chest tightness
(British Thoracic Society guidelines, 1997). At enroll-
ment, patient’s medical history and general physical
condition were recorded. A spirometry, a chest X-ray,
blood gases analysis, laboratory tests and breath con-
densate collection were also carried out. All these
measurement were taken in patients with acute exacer-
bation of COPD before starting a course of a broad
spectrum antibiotic (T0) and then repeated after 2 weeks
when in a stable condition [no respiratory symptoms, no
signs of infection, stable forced expiratory volume in one
second (FEV1) and spirometric bronchodilator response
to 500 Ag nebulised salbutamol b15% of the baseline;
T1]. At this time, 15 COPD patients enrolled received
mucolytic therapy (SCMC-Lys 2.7 g daily administrated
orally, supplied by Dompe`, L’Aquila, Italy; group A),
while the other 15 remained untreated (group B) for 6
months (T2). During this period, only further inhaled
G.E. Carpagnano et al. / European Journal of Pharmacology 505 (2004) 169–175 171steroids and long-acting B2-agonist were allowed. None
of patients included were treated with oral steroids. The
patients had taken at least 80% of his medication in order
to be considered compliant. Throughout the study, each
patient visited the hospital each month for clinical check.
All adverse events were recorded, and their relationships
to tested medication were assessed. No patient presented
a new exacerbation during this period.
After 6 months, COPD patients enrolled in the study
were recalled for the end-study visit and the last spirometry,
blood gases analysis, laboratory tests and breath condensate
collection (T2; Table 2).
2.2. Study design
This study was designed to investigate the inflammation
and the oxidative stress in airways of COPD patients with
acute exacerbation of disease and in stability and to assess
the anti-inflammatory and antioxidant effects of a 6-month
treatment with SCMC-Lys.
2.3. Pulmonary function testing
Pulmonary function tests were performed prior to the
measurement of exhaled breath condensate (EBC). Forced
expiratory volume in one second (FEV1), vital capacity
(FVC) and FEV1/FVC ratio were measured using a dry
spirometer (PK Morgan, Gillingham, UK). The highest
value of three maneuvers was expressed as a percentage of
the predicted normal value.Table 2
Acute COPD subjects at T0, T1 and T2
COPD with
acute
exacerbation
(T0) n=30
COPD after 2
weeks of antibiotic
treatment
(T1) n=30
COPD after
mucolytic
therapy
(T2) n=15
FEV1
(%predicted)
62.5F2.9 74.4F2.6* 75.1F3.2#
FVC
(%predicted)
77.1F1.6 84.2F1.8* 87.6F2.2#
PaO2
(mm Hg)
59.1F2.2 76.7F3.5** 75.7F2.4#
PaCO2
(mm Hg)
44.6F1.9 39.8F2.1* 40.3F1.8#
Buccal
temperature (8C)
38.3F0.7 36.1F0.6* 36.9F1.1#
Blood neutrophil
count (109/l)
14.2F3.0 6.1F1.4** 6.8F1.6##
CRP (mg/dl) 7.9F2.9 1.2F1.1** 0.8F0.9##
Definition of abbreviations: FEV1—forced expiratory volume in one
second; FVC—forced vital capacity; CRP—C-reactive protein. All data
are expressed as meansFS.D.
* pb0.05.
** pb0.01 (T0 vs. T1).
# pb0.05.
## pb0.01 (T0 vs. T2).2.4. Exhaled breath condensate and assay
Exhaled breath condensate was collected by using an
EcoScreen (Jaeger, Wurzburg, Germany). The subjects
breathed through a mouthpiece and a two-way nonrebreath-
ing valve, which also served as a saliva trap. They were asked
to breathe at a normal frequency and tidal volume, wearing a
nose clip, for a period of 10 min. If subjects felt saliva in their
mouth, they were instructed to swallow it. Condensate, at
least 1 ml, was collected as ice at 20 8C, transferred to
Eppendorf tubes and immediately stored at70 8C. Samples
were analysed within 3 months from collection.
To exclude saliva contamination, amylase activity was
analysed in exhaled breath condensate (EBC).
A specific enzyme immunoassay kit (Cayman Chemical,
Ann Arbor, MI) was used to measure 8-isoprostane and
Interleukine-6 concentrations in breath condensates. The
assay was previously validated directly by gas chromatog-
raphy/mass spectrometry (Carpagnano et al., 2003a,b;
Montuschi et al., 2000). The intra-assay and interassay
variability were V10%. The detection limit of the assays was
4 and 1.5 pg/ml, respectively.
2.5. Statistical analysis
Data were expressed as meansFS.D. A Mann Whitney
test to compare groups and a Wilcoxon matched paired test
were used, and correlations between variables were per-
formed using Spearman’s rank correlation test. Significance
was defined as a p value of b0.05. The reproducibility of
assays was assessed in a separate experiment through the
Bland and Altman method, and the coefficient of variation
was determined (Bland and Altman, 1996).3. Results
All patients tolerated the SCMC-Lys without any
complaints of side effects. The lung function parameters
(FEV1, FVC), the blood gases and the plasmatic neutrophils
and PCR showed an improvement in COPD patients
hospitalized for acute exacerbation after 2 weeks of
antibiotics but did not indicate any significant differences
after treatment with SCMC-Lys (Table 2).
No amylase activity was detected in any exhaled breath
condensate sample.
3.1. 8-isoprostane
Exhaled 8-isoprostane levels were markedly high in
subjects admitted in the hospital for acute exacerbations of
COPD (T0; 21.8F5.1 pg/ml) compared to stable COPD
(13.2F2.0, pb0.001) and healthy controls (4.7F1.8 pg/ml,
pb0.0001; Fig. 1A). Exhaled 8-isoprostane values fell
significantly in acute COPD after 2 weeks of treatment with
antibiotic treatment (T1 vs. T0; 21.8F5.1 vs. 14.3F5.4 pg/
Fig. 1. 8-isoprostane (A) and interleukin-6 (B) concentrations in exhaled
breath condensate of healthy and acute COPD and stable COPD subjects.
Mean values are indicated by horizontal bars.
Fig. 2. Exhaled 8-isoprostane (A) and IL-6 (B) concentrations in 15 COPD
patients treated for 6 months with SCMC-Lys.
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concentrations was observed in 15 COPD subjects treated
for 6 months with SCMC-Lys (group A; 8.9F1.5 vs.
13.2F6.2 pg/ml, pb0.0001; Fig. 2A). However, the 8-
isoprostane levels in exhaled breath condensate of remaining
15 COPD patients who did not received any therapy (group
B) did not change significantly over 6 months (12.7F3.8 vs.
15.4F4.5 pg/ml; T2; Fig. 3A). Concentrations of exhaled 8-
isoprostane were significantly lower in group A than in
group B at T2 (8.9F1.5 vs. 12.7F3.8, pb0.005).
No correlation was found between exhaled 8-isoprostane
concentration and FEV1 or FVC.
Reproducibility of exhaled 8-isoprostane measurements
was assessed in 10 nonsmoking normal and 10 COPD
subjects. In the majority of measurements, the differences
between the two 8-isoprostane values lay within F2S.D.
[0.14(0.32) and 0.08(1.09) pg/ml]. The coefficients of
variation for 8-isoprostane were 4.4% and 3.7%.
3.2. Interleukin-6
Exhaled Interleukine-6 levels were markedly high in
subjects admitted in the hospital for acute exacerbations ofCOPD (T0; 7.4F0.9 pg/ml) compared to stable COPD
(5.8F0.2 pg/ml, pb0.001) and healthy controls (2.7F0.6
pg/ml, pb0.0001; Fig. 1B).
Exhaled Interleukine-6 values fell significantly in acute
COPD after 2 weeks of treatment with antibiotic (T1 vs. T0;
7.4F0.9 vs. 6.0F0.5 pg/ml, pb0.0001).
A further reduction of exhaled Interleukine-6 concen-
trations was observed in 15 COPD subjects treated for 6
months with SCMC-Lys (group A; 6.0F0.4 vs. 4.6F0.8 pg/
ml, pb0.0001; Fig. 2B).
However, the Interleukine-6 levels in exhaled breath
condensate of the remaining 15 COPD patients who did not
received any therapy (group B) did not change significantly
over 6 months (5.7F0.5 vs. 5.9F0.6 pg/ml; T3; Fig. 3B).
Concentrations of exhaled Interleukine-6 were significantly
lower in group A than in group B at T2 (8.9F1.5 vs.
12.7F3.8, pb0.005).
There was a positive correlation between exhaled
Interleukine-6 and exhaled 8-isoprostane (r=0.8, pb0.0001;
Fig. 4).
Reproducibility of exhaled Interleukine-6 measurements
was assessed in 10 nonsmoking normal and 10 COPD
subjects. In the majority of measurements, the differences
between the two Interleukine-6 values lie within F2S.D.
Fig. 3. Exhaled 8-isoprostane (A) and IL-6 (B) concentrations in 15 COPD
patients untreated for 6 months.
G.E. Carpagnano et al. / European Journal of Pharmacology 505 (2004) 169–175 173[0.03(0.24) and 0.04(0.89) pg/ml]. The coefficients of
variation for Interleukine-6 were 5.9% and 6.4%.Fig. 4. Correlation between exhaled IL-6 and exhaled 8-isoprostane
concentrations in healthy and COPD subjects.4. Discussion
This study showed significantly higher concentrations of
8-isoprostane and Interleukine-6 in the breath condensate of
COPD subjects than in healthy controls, especially during
an acute exacerbation of the disease. Both these markers
presented a marked reduction after 6 months of daily
administration of carbocysteine lysine salt monohydrate
(SCMC-Lys) in COPD subjects. However, an improvement
of lung function after mucolytic drug was not watched.
Finally, a positive correlation was observed between
exhaled Interleukine-6 and 8-isoprostane concentrations.
This is one of the first studies showing longitudinal data on
markers in EBC.
The inflammation and the oxidative stress are implicated
in the pathogenesis and progression of COPD (Paredi et al.,
2002). Elevated concentrations of oxidative stress markers
(hydrogen peroxide, 8-isoprostane and ethane, etc.) as well
as inflammatory markers (Leukotriene B4, Interleukin-6,
etc.) demonstrated in breath condensate (Biernacki et al.,
2003; Carpagnano et al., 2003a,b; Dekhuijzen et al., 1996;Montuschi et al., 2000; Paredi et al., 2000), blood
(Brandolini et al., 2003; Malo et al., 2001) and urine of
patients with COPD patients (Partico et al., 1998), support
their key role.
However, monitoring inflammation and oxidative stress
in COPD is difficult and may not be reflected by changes in
blood and urine markers (Paredi et al., 2002). For this
reason, in this study, we use a bodily fluid that reflects
airways situation, the breath condensate. The recent interest
that this lung’s sample is generating is justified by its several
advantages compared to other distrectual samples (bron-
choalveolar lavage, induced sputum and lung biopsy), such
as its completely noninvasiveness, simplicity, practicity and
tolerability (Kharitonov and Barnes, 2001a,b).
We measured in the breath condensate of COPD patients
the 8-isoprostane (8-epi-prostaglandin-F2a), the predomi-
nant isoprostane formed in humans used as quantitative
index of oxidative stress in vivo and the interleukin-6, a
proinflammatory cytokine produced by epithelial cells and
macrophages, expressed in response to various inflamma-
tory stimuli (Carpagnano et al., 2003a,b; Montuschi et al.,
2000). The increased exhaled concentrations of both
markers that we found in COPD compared to healthy
controls further confirm the presence of a marked inflam-
mation and oxidative stress in their airways.
We enrolled in this study COPD patients hospitalized for
an acute exacerbation of COPD. In agreement with
Biernacki et al. (2003), we observed a further increase of
inflammatory and oxidative stress markers in the breath
condensate of these patients that significantly fall after 2
weeks of treatment with antibiotics (Partico et al., 1998). We
believe that the higher exhaled 8-isoprostane concentrations
that we found in acute COPD patients may be due to their
more severe conditions as evidenced by the necessity of
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who select its patients in a general practice clinic (Biernacki
et al., 2003). Our results are also consistent with recent
reports that showed a significant augment of other inflam-
matory markers in the sputum of patients with bacterial
exacerbation of COPD that fall rapidly after antibiotic
treatment (Bhowmik et al., 2000; Crooks et al., 2000).
The increased burden of oxidative stress further amplifies
the inflammatory response. The increased concentrations
that we found of exhaled Interleukine-6, which mirror that
of exhaled 8-isoprostane, may be mediated through an
increase in nuclear factor-nB, a transcription factor that is
activated by oxidative stress and switches on the tran-
scription of inflammatory genes, such as Interleukine-6
(Barnes, 2000). We believe that the correlation observed
between exhaled 8-isoprostane and Interleukine-6 levels
may support this hypothesis.
This study further wanted to investigate possible effects
of carbocysteine lysine salt monohydrate (SCMC-Lys) on
inflammation and oxidative stress in airways of humans.
At this aim, 15 COPD subjects underwent 6 months of
daily therapy with SCMC-Lys, a some dosage of 2.7 g,
used in a previous study in which this drug resulted
efficacy and was sure in the prevention of riacutization of
COPD (Allegra et al., 1996). SCMC-Lys, whose ther-
apeutic efficacy is commonly related to the ability to
replace fucomucins by sialomucins, is often administrated
in COPD patients for the positive effects demonstrated in
several clinical studies in the treatment of COPD (Allegra
et al., 1996; Edwards et al., 1976; Miskovitis et al.,
1982).
As a result of the present work, we showed that SCMC-
Lys acts by reducing the 8-isoprostane concentrations in
breath condensate of healthy and COPD subjects when
given continuously for 6 months.
Breath condensate has been previously used in a similar
pharmacological study where the effects of a common
mucolytic drug, the N-acetylcysteine (NAC), were tested on
the oxidative stress in subjects with COPD (Brandolini et
al., 2003). In this referred study, long-term administration of
NAC showed to reduce two oxidative stress markers, the
H2O2 and the TBARs, in the breath condensate of COPD
patients (Brandolini et al., 2003). Although the antioxidant
action of NAC and others thiol-containing mucolytic drugs
has been largely confirmed by this and other several studies,
the capacity of SCMC-Lys as a scavenger of reactive
oxygen intermediates has been underestimated until now.
Few evidences in fact appear in literature to confirm of
our findings, between those the one of Brandolini et al.
(1996) that showed antioxidant properties of SCMC-Lys in
cell-free and cellular systems. Only some years later,
confirming his previous results, Brandolini et al. observed
that SCMC-Lys acts as a selective scavenger of superoxide
(HOCL) and hydroxyl radicals (OH8) through oxidation of
its thioether group and compared the scavenger capacity of
SCMC-Lys to that of GSH (Barnes, 2003).The antioxidant properties of SCMC-Lys have been also
previously confirmed in vitro in three different oxygen
radical producing systems represented by BAL from COPD
patients, ultrasound treated human serum and cultured
human lung endothelial cells challenged with elastase
(Pinamonti et al., 1996). In these systems, Pinamonti et al.
(1996) also disclosed the antiradical activity of SCMC-Lys
towards HOCL and OH and against elastase-induced
superoxide production.
In this study, we also showed a reduction of an
inflammatory marker, the Interleukine-6 in COPD and
healthy subjects, after SCMC-Lys therapy. Ours is not the
only finding at this regard. Asti et al. (1995) first supposed
that this mucolytic drug can exert an anti-inflammatory
action demonstrating that SCMC-Lys acts reducing neutro-
phil infiltration induced within the airways by intratracheal
injection of IL-1 beta. The anti-inflammatory power of
SCMC-Lys has also been previously confirmed by Pina-
monti et al. (2001) who experimentally showed a decrease
in exudates volume and the leukocyte recruitment mediated
by SCMC-Lys after pleural inflammation induced by
injection of carrageenan.
Although the present study sustains the supposed anti-
inflammatory and antioxidant effects of SCMC-Lys, it did
not show to improve lung function parameters as well as the
other mucolytic drugs (Mesna or NAC; Schreiber et al.,
2002). We believe that this finding could explain the lack of
correlation that we observed between exhaled Interleukine-6
and 8-isoprostanes and lung function parameters.
However, the spirometric changes associated with
exacerbation of COPD are usually very small, so lung
function tests are not very useful in detecting exacerbations
and are not expected to correlate with inflammatory and
oxidative stress markers in airways (Aaran et al., 2001).
In conclusion, our results support the existence of an
enhanced inflammation and oxidative stress in airways of
COPD subjects that significantly increase during acute
exacerbations. They also suggest the usefulness of
exhaled markers as the Interleukine-6 and the 8-isopros-
tane in the clinical management of this widespread
respiratory disease.
Furthermore, the reduction of exhaled Interleukine-6
and 8-isoprostane concentrations observed in COPD
subjects after short-term administration of SCMC-Lys
suggests anti-inflammatory and antioxidant actions of this
drug that should be confirmed by a placebo-controlled
study. However, further studies are required to elucidate
the exact mechanism responsible for the decrease of the
inflammation and the oxidative stress mediated by
SCMC-Lys.Acknowledgement
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